Roland Wilhelm Kolbeck - 01 Aug 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Scientific Officer
Signature: /s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 01 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 05 Aug 2025, 16:33:44 UTC
Previous filing: 05 Aug 2025
Next filing: 06 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kolbeck Roland Wilhelm	Chief Scientific Officer	C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE	/s/ Matthew Rothman, Attorney-in-Fact	05 Aug 2025	0002076327

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Award	$0	+145,500		$0.000000	145,500	01 Aug 2025	Common Stock	145,500		Direct	F1, F2
transaction	ACRS	Employee Stock Option (right to buy)	Award	$0	+510,000		$0.000000	510,000	01 Aug 2025	Common Stock	510,000	$1.53	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3	Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.